Refractory period (sex) for treating sexual dysfunction. Sildenafil, used in the treatment of erectile dysfunction, was found in one scientific study to have caused "a decreased postejaculatory erectile refractory time (3.2 ± 0.7 vs. 6.4 ± 0.7 minutes)" in men diagnosed with premature ejaculation. It is additionally proposed that the gonadotropin inhibitory hormone (GnIH), which is considered to inhibit the hypothalamic-pituitary-gonadal axis and sexual functions causes refractoriness of the post-ejaculatory refractory period. This hypothesis also supports the increase of oxytocin and prolactin after orgasm in accordance with the previous studies. One alternative theory explains the male refractory period in terms of a peripheral
Growth-hormone-releasing hormone receptor to date. Growth-hormone-releasing hormone receptor The growth-hormone-releasing hormone receptor (GHRHR) is a G-protein-coupled receptor that binds growth hormone-releasing hormone. The GHRHR activates a Gs protein that causes a cascade of cAMP via Adenylate cyclase. This gene, expressed in the pituitary, encodes a receptor for growth-hormone-releasing hormone. Binding of this hormone to the receptor leads to synthesis and release of growth hormone. Mutations in this gene have been associated with isolated growth-hormone deficiency (IGHD), also known as Dwarfism of Sindh, a disorder characterized by short stature. Many alternate transcriptional splice variants encoding different isoforms have been described, but only two have